Objective-Angiotensin-converting enzyme (ACE) is present in many cell types of atherosclerotic lesions. This study determined whether ACE activity in endothelial and smooth muscle cells (SMCs), 2 major resident cell types of the aorta, contributes to hypercholesterolemia-induced atherosclerosis. Approach and Results-All study mice were in low-density lipoprotein receptor −/− background. To determine the contribution of ACE on endothelial cells to atherosclerosis, female ACE floxed mice were bred to male Tie2-Cre transgenic mice. Endothelial cell-specific deletion of ACE significantly decreased serum ACE activity, but had no effect on systolic blood pressure and atherosclerosis. Because ACE protein is present on SMCs, the most abundant cell type of the aorta, we then determined whether ACE on SMCs contributes to atherosclerosis. ACE was depleted from SMCs by breeding female ACE floxed mice with male SM22-Cre transgenic mice. SMC-specific deficiency of ACE did not affect ACE activity in serum, but ablated its presence and activity in the aortic media. Although SMC-specific deficiency of ACE had no effect on systolic blood pressure, it significantly attenuated hypercholesterolemia-induced atherosclerosis in both male and female mice. Conclusions-These studies provide direct evidence that ACE derived from endothelial cells does not play a critical role in atherosclerosis. Rather, SMC-derived ACE contributes to atherosclerosis, independent of circulating ACE activity and blood pressure.
A ngiotensin (Ang) II is a major regulator of blood pressure and atherosclerosis. 1 Endogenous AngII is derived exclusively from angiotensinogen. 2 Although there are evolving complexities of the renin-angiotensin system, the major initial step is renin cleavage to release AngI. Angiotensinconverting enzyme (ACE) is the major enzyme that converts AngI into AngII. 3 The role of ACE in blood pressure and atherosclerosis has been demonstrated in both experimental studies [4] [5] [6] [7] [8] [9] [10] and human trials 11, 12 using ACE inhibitors. ACE is abundant in atherosclerotic lesions where it is expressed in many cell types. [13] [14] [15] [16] [17] A potential role of local ACE in atherosclerosis has been studied previously using genetically manipulated mice. 18 One approach used ACE2/2 mice that lack membrane-bound ACE. 19 Inability of ACE to tether to cellular membranes in apolipoprotein E −/− mice led to low serum ACE activity, lack of ACE activity in lung and vessels, low blood pressure, and less atherosclerosis. 18 Another approach is the ACE3/3 mouse, in which ACE expression is found predominantly in liver and minimally in kidney, but absent in lung and arteries. 20 This manipulation of ACE does not affect serum ACE activity and has no effects on blood pressure and atherosclerosis. Although findings from ACE2/2 mice implicate the importance of local ACE on atherosclerosis, findings from ACE3/3 mice do not support this assumption. It is worth noting that ACE3/3 mice have 50-to 100-fold higher expression of ACE in hepatocytes than wild-type mice, 20 which may not represent a pathophysiological relevant condition. In addition, neither mouse model provides direct evidence whether ACE on resident cells of the arterial wall contributes to atherosclerosis.
Macrophages are the predominant cell type in atherosclerotic lesions. We have shown that ACE inhibition by enalapril ablates atherosclerosis, 10 but leukocyte-derived ACE only has a modest contribution to atherosclerosis in hypercholesterolemic mice, 21 suggesting that other cell types may also play roles on atherogenesis. In human atherosclerotic lesions, ACE is present in both endothelial and smooth muscle cells (SMCs). [22] [23] [24] To determine cell-specific effects of ACE in atherosclerosis, we developed ACE floxed mice and bred them to Cre trangenic mice in a low-density lipoprotein receptor −/− background. Although endothelial cell (EC)-specific deficiency of ACE profoundly reduced systemic ACE activity, it did not reduce atherosclerosis. In contrast, ACE activity in SMCs has a major impact on atherosclerotic lesion size.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

EC-Specific ACE Deficiency Had No Effects on Systolic Blood Pressure and Atherosclerosis
All study mice were in an low-density lipoprotein receptor −/− background. EC-specific deficiency of ACE was achieved by cross-mating female ACE floxed mice to male Tie2-Cre hemizygous mice. ACE deficiency in ECs (Ace Figure III in the online-only Data Supplement), systolic blood pressure ( Figure 1D ), and plasma total cholesterol concentrations ( Figure 1E ). The low serum ACE activity in Ace EC−/− mice did not mitigate atherosclerosis, as demonstrated by both en face measurements of the ascending, arch and part of descending thoracic regions ( Figure 1F ) and sections throughout aortic roots ( Figure IV in the onlineonly Data Supplement).
SMC-Specific ACE Deficiency Had No Effect on Systolic Blood Pressure, but Attenuated Atherosclerosis
ACE is abundant in aortic SMCs. 21 To determine whether ACE in SMCs plays a critical role on atherosclerosis, we developed SMC-specific ACE deficient (Ace Endothelial cell-specific angiotensinconverting enzyme (ACE) deficiency diminished circulating ACE activity, but had no effects on systolic blood pressure and atherosclerosis in low-density lipoprotein receptor −/− mice. A, Western blotting of ACE, CD31, and β-actin in serum and lung; ACE activities in serum (B) and lung (C) were measured using a fluorimetric method. *P=0.001 by Student t test, and #P=0.002 by Mann-Whitney rank-sum test. D, Systolic blood pressure was measured using a tail-cuff system. P=0.2 by Student t test. E, Plasma total cholesterol concentrations were measured enzymatically using a commercial kit. P=0.8 by Student t test. F, Atherosclerotic lesion area from the ascending aorta to 3 mm below the subclavian artery was measured by an en face method. Percent lesion area=(total lesion area/total intimal area)×100%. and Ace SMC−/− mice (Ace SMC+/+ versus Ace SMC−/− : 133±18 versus 114±7 nmol His-Leu/min per milliliter; P=0.3 by MannWhitney rank-sum test). ACE deficiency in SMCs had no effect on plasma AngI and AngII concentrations, systolic blood pressure ( Figure 2D ), and plasma total cholesterol concentrations ( Figure 2E ). ACE deficiency in SMCs significantly ameliorated atherosclerosis when compared with wildtype littermates, as assessed by en face method ( Figure 2F ). Similarly, in female mice, ACE deficiency in SMCs had no effects on serum ACE activity, systolic blood pressure, and plasma total cholesterol concentrations, but had reduced atherosclerosis ( Figure 
Discussion
It has been speculated that ACE in serum is originated from pulmonary vascular endothelium. 28 To our knowledge, this study provides direct evidence that ACE derived from ECs contributes to its systemic presence. However, this contribution accounts for only 50% of systemic ACE activity. We have demonstrated that Tie2 promoter in Cre transgenic mice leads to depletion of target genes on ECs of lungs and major arteries including the aorta. SMC-derived ACE does not account for its systemic presence because its deficiency does not affect serum ACE activity. In our previous study using bone marrow transplantation approach, we have demonstrated that serum ACE activity is not influenced by leukocyte-derived ACE. 21 Several mouse models have been developed with specific cell-restricted overexpression of ACE including ACE overexpression in hepatocytes (ACE3/3), cardiac myocytes (ACE8/8), and macrophages (ACE10/10). All these 3 mouse models, with absence of ACE in lung, aorta, and other vessels, have comparable serum ACE activity as wild-type littermates, 20, 29, 30 implicating that ACE expression on arterial wall is not necessary for maintaining normal systemic ACE activity. However, all these mouse models have 50-to 100-fold higher ACE expression in restricted cell types than wildtype littermates. It is unclear whether these cell types, under a physiological condition or a pathophysiological relevant state, contribute to systemic ACE activity. Therefore, it is currently unknown, in addition to ECs, which cell types contribute to the other 50% of circulating ACE.
Pharmacological inhibition or global genetic depletion of ACE in mice reduces blood pressure, which is consistent in both human studies and animal models. 10, 11, 31, 32 These previous studies do not define the source of ACE that contributes to blood pressure regulation. In the present study, profound reductions of ACE activity in serum of Ace EC−/− mice do not affect systolic blood pressure. Blood pressure is also not regulated by ACE in leukocytes 21 or SMCs (the present study). AngII regulates blood pressure through its interaction with angiotensin type 1a receptor (AT1a) receptors. Although AngII-induced increases in blood pressure have been assumed to be via stimulation of AT1a receptors on SMCs, deletion of AT1a receptors on this cell type had no effect on blood pressure during infusion of AngII. 33, 34 Rather, AT1a receptor in proximal convoluted tubules of kidney contributes to AngII-mediated blood pressure changes. 33 It would be interesting to determine whether the lack of effects on blood pressure in SMC-specific ACE deficient mice is because of its regulation by other cell types, Figure 2 . Smooth muscle cell-specific angiotensin-converting enzyme (ACE) deficiency reduced aortic ACE activity and atherosclerosis in lowdensity lipoprotein receptor −/− mice. A, Western blotting of ACE, CD31, and β-actin in whole aorta (consisting of endothelium and aortic media) and aortic media alone; ACE activity was measured using a fluorimetric method in whole aorta (B) and aortic media alone (C). *P=0.01 (B) and <0.001 (C) by Student t test, respectively. D, Systolic blood pressure was measured using a tail-cuff system. P=0.8 by Mann-Whitney rank-sum test. E, Plasma total cholesterol concentrations were measured enzymatically using a commercial kit. P=0.5 by Student t test. F, Atherosclerotic lesion area from the ascending aorta to 3 mm below the subclavian artery was measured by an en face method. Percent lesion area=(total lesion area/total intimal area)×100%. ▼, individual data; •, means of each genotype, and error bars, SEM. *P=0.005 by Student t test. such as epithelial cells of the proximal convoluted tubules in kidney. 33 In addition to blood pressure, another unexpected finding in the present study is that EC-derived ACE has no effects on atherosclerosis although it attributes to 50% of circulating ACE. SMCs are the predominant cell type of the arterial wall. ACE is readily detectable in vascular SMCs as demonstrated in our previous 21, 25 and the present studies. ACE is also abundant in SMCs of atherosclerotic lesions and is elevated during progression of atherosclerosis. 13, 14, 35 Although ACE deletion in SMCs does not change serum ACE activity and blood pressure, it leads to 50% reduction of atherosclerotic lesions. This is not a sex-specific effect because there are also significant reductions of atherosclerosis in female Ace SMC−/− mice. These findings, combined with our previous findings that ACE deficiency on leukocytes has no effects on serum ACE activity and blood pressure, but reduces atherosclerosis (≈50% reductions), 21 have provided insights into several aspects. First, locally derived ACE, rather than systemic ACE, is a contributor to hypercholesterolemia-induced atherosclerosis. Second, blood pressure is not a contributor to ACE-mediated atherosclerosis. Third, macrophages and SMCs are the 2 major cell types for ACE to promote atherosclerosis in hypercholesterolemic mice.
There have been consistent demonstrations that inhibition of AngII and AT1a receptor pathway profoundly reduces atherosclerosis in hypercholesterolemic mice. 25, 36 However, the location of AngII synthesis and cell type(s) in which AT1a receptors are activated have yet to be completely resolved.
26,37-40 SMCspecific deletion of AT1a receptor does not influence atherosclerosis. 40 Therefore, it is unlikely that reduced atherosclerosis in mice with SMC-specific deficiency of ACE is attributed to ablated interaction between AngII and AT1a receptor in SMCs. AngII has both autocrine and paracrine effects and hence may affect neighboring cells. To understand by which mechanisms ACE derived from SMCs contributes to atherosclerosis will require the determination of which cell type is stimulated via AT1a receptors to promote atherogenesis.
In summary, using 2 cell-specific ACE deficient mouse models, we show that ACE derived from SMCs contributes to the development of atherosclerosis in a blood pressure-and sex-independent mechanism.
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